

high-risk non-valvular atrial fibrillation (NVAf) and genetic variants of VKORC1.

**Methods** 151 patients with NVAf and the allelic mutation of VKORC1 gene-1639G>A and a CHADS<sub>2</sub> score of 2 and above were randomly divided into two groups. One group was warfarin maintenance dosing adjustment nomogram for INR goal of 2–3, the other group was aspirin (100 mg/d) combined BNC (1.6 g thrice daily) as antithrombotic drug. All drugs were taken at least 1 year and clinical events (ischaemic stroke, haemorrhage, death) were followed up.

**Results** Baseline clinical data were similar in both groups. Ischaemic stroke and the all-cause death did not significant difference between two groups. The serious bleeding rate of the combined group was less than that of the adjusted-dose warfarin group (0% vs 7.9%, OR=0.921, 95% CI 0.862 to 0.984, p=0.028).

**Conclusions** Aspirin combined BNC and the adjusted-dose warfarin was equally effective in elderly patients with NVAf for prevention of ischaemic stroke. The combination therapy could reduce the risk of the antithrombotic drug therapy-associated bleeding.

GW23-e1340

**COMPARISON OF ASPIRIN COMBINED NAOXINTONG VERSUS ADJUSTED-DOSE WARFARIN IN ELDERLY PATIENTS WITH HIGH-RISK NON-VALVULAR ATRIAL FIBRILLATION AND GENETIC VARIANTS OF VKORC1**

doi:10.1136/heartjnl-2012-302920a.225

Chen Hui, Wu Xiaoying, Chen Hui. *Fujian Provincial Cardiovascular Disease Institute*

**Objectives** Adjusted-dose warfarin and aspirin reduce stroke in patients with atrial fibrillation, and warfarin is substantially more efficacious than aspirin. But patients especially in Chinese population with genetic variants of vitamin K epoxide reductase (VKORC1), who received warfarin had more than as many haemorrhages than those who received aspirin.

**Objective** To compare between aspirin combined BNC versus adjusted-dose warfarin in more than 65 years of age patients with

**Heart**

# COMPARISON OF ASPIRIN COMBINED NAOXINTONG VERSUS ADJUSTED-DOSE WARFARIN IN ELDERLY PATIENTS WITH HIGH-RISK NON-VALVULAR ATRIAL FIBRILLATION AND GENETIC VARIANTS OF VKORC1

Chen Hui, Wu Xiaoying and Chen Hui

*Heart* 2012 98: E86

doi: 10.1136/heartjnl-2012-302920a.225

---

Updated information and services can be found at:  
[http://heart.bmj.com/content/98/Suppl\\_2/E86.2](http://heart.bmj.com/content/98/Suppl_2/E86.2)

---

*These include:*

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

**Topic Collections**

Articles on similar topics can be found in the following collections

[Drugs: cardiovascular system](#) (8839)

---

**Notes**

---

To request permissions go to:  
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:  
<http://group.bmj.com/subscribe/>